HB-002.1T is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase I for Extrahepatic Bile Duct Cancer. According to GlobalData, Phase I drugs for Extrahepatic Bile Duct Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the HB-002.1T LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HB-002.1T overview
HB-002.1T is under development for the treatment of solid tumors including lung cancer, colorectal cancer, breast cancer, gastric cancer, ovarian cancer, cervical cancer, head and neck cancer, biliary tract tumors , Pancreatic cancer, bladder cancer, nasopharyngeal cancer, metastatic ovarian cancer, metastatic biliary tract cancer, intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, gallbladder cancer, metastatic pancreatic cancer, fallopian tube cancer or primary peritoneal cancer, endometrioid carcinoma. It is administered through intravenous route. The drug candidate is developed based on recombinant fusion protein technology. It acts by targeting vascular endothelial growth factor receptor (VEGFR).
It was under development for breast cancer, colorectal cancer and lung cancer.
Huabo Biopharm (Shanghai) overview
Huabo Biopharm Co Ltd (Huabobio), a subsidiary of Shanghai Huaota Biopharmaceutical Co Ltd, is a developer and marketer of therapies for the treatment of patients with tumors. The company develops drugs by using a bi-functional protein technology platform, domain protein technology and antibody engineering technology. Its pipeline products include HOT-101, HB0030, HB0025, HB002.1T, HOT-1030, HB0028, HB0036 and HB0039, among others. Huabobio’s antibody engineering technology and bi-functional protein technology platform support in development of protein and antibody drugs with improved therapeutic efficacy. The company promotes tumor metastasis at the late stage of tumor progression through inducing epithelial-mesenchymal transition, inhibiting tumor immunity; and tumor angiogenesis through induction of angiogenic mediators such as vascular endothelial growth factor. Huabobio is headquartered in Shanghai, China.
For a complete picture of HB-002.1T’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
